FDA delays preference on Pfizer, Bristol-Myers drug

<p><span>Federal regulators</span> have again behind a preference on either to approve a rarely touted initial anticlotting drug <span>Eliquis</span> grown by <span>Pfizer Inc.</span> and <span>Bristol-Myers Squibb Co.</span></p>
<p>The <span>Food and Drug Administration</span> wants some-more information on information government and corroboration from a outrageous general investigate that examined cadence impediment in patients with an <span>irregular heartbeat</span> called <span>atrial fibrillation</span>, a drugmakers pronounced Monday.</p>
<p>The companies pronounced regulators did not ask for new studies in their response letter, and they devise to work fast to residence superb questions. Even so, a <span>Bristol-Myers</span> mouthpiece pronounced a group could take adult to 6 months to examination their response.</p>
<p>“We are already operat...